We are live on ! Find out more
NVAX icon

Novavax

235 hedge funds and large institutions have $792M invested in Novavax in 2025 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 69 increasing their positions, 77 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

8.1% more ownership

Funds ownership: 63.55%71.65% (+8.1%)

6% less funds holding

Funds holding: 250235 (-15)

10% less repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 77

12% less capital invested

Capital invested by funds: $895M → $792M (-$103M)

20% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 44

31% less call options, than puts

Call options by funds: $46.7M | Put options by funds: $67.8M

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
235
Holders Change
-15
Holders Change %
-6%
% of All Funds
2.84%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.02%
New
35
Increased
69
Reduced
77
Closed
44
Calls
$46.7M
Puts
$67.8M
Net Calls
-$21.1M
Net Calls Change
+$2.64M

NVAX Hedge Fund Activity: Q4 2025 in Review

235 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q4 2025, worth a combined $792M — down 12% from $895M a quarter earlier.

Sellers outnumbered buyers: 44 funds closed out of NVAX and 35 opened new positions — a net loss of 9 holders — while 77 trimmed existing stakes and 69 added.

The largest buyer was Bank of America, adding an estimated $39.1M. The largest seller was Coatue Management, exiting entirely with an estimated $33.3M sold.

  • 235 institutional investors held Novavax (NVAX) as of Q4 2025, down from 250 in Q3 2025.
  • Funds reported $792M of Novavax stock for Q4 2025, down 12% quarter-over-quarter.
  • 35 funds opened new Novavax positions in Q4 2025 and 44 closed out, a net change of -9 holders.
  • The largest Novavax buyer in Q4 2025 was Bank of America, an estimated $39.1M added.
  • The largest Novavax seller in Q4 2025 was Coatue Management, an estimated $33.3M sold.

Based on aggregated 13F filings for Q4 2025.